Last reviewed · How we verify

NCT07525726

The Relationship Between Finger Ratio and Development in Infants

ENROLLING BY INVITATION Last updated 15 April 2026
What this trial tests

trial testing Digit Ratio in Infant Developmental Assessment in 80 participants. Enrolling by invitation.

Timeline
6 April 2026
Primary endpoint
1 April 2027
1 April 2027

Quick facts

Lead sponsorNigde Omer Halisdemir University
StatusENROLLING BY INVITATION
Study typeOBSERVATIONAL
Enrollment80
Start date6 April 2026
Primary completion1 April 2027
Estimated completion1 April 2027
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Nigde Omer Halisdemir University

Who can join

Adults 12 Months to 18 Months, any sex, with Infant Developmental Assessment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

One of the most prominent indicators of prenatal androgen exposure is considered to be the ratio of second and fourth finger lengths (2D:4D). The 2D:4D finger ratio refers to the ratio of the length of the second finger (2D; index finger) and the fourth finger (4D; ring finger). Evidence suggests that 2D:4D is developmentally stable and stabilizes from the second trimester of pregnancy. It has been reported that the 2D:4D ratio correlates positively with estrogen and negatively with testosterone. In both sexes, prenatal testosterone levels are inversely related by a 2D:4D ratio, which does not change with age. Androgens can have direct trophic effects on target cells or indirectly affect neuronal growth through neurotrophic mediators released locally by steroid-sensitive neuronal or glial cells. Prenatal testosterone can have long-term organizational effects on the structure and function of various body systems (e.g., cardiovascular and musculoskeletal systems) that are important for physical activity and exercise.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Nigde Omer Halisdemir University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07525726.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing